MALDI-2 Increases Small Molecule Sensitivity
by One or Two Orders of Magnitude New prm-PASEF Workflow for
Translational 4D Proteomics Large-Scale, High-Precision
Peptide CCS Measurements for Deep Learning Short-gradient
dia-PASEF Methods for High Throughput 4D Proteomics Unique
CCS-enabled Mobility Offset Mass Aligned (MOMA) for Identification
of Isobars ‘Run & Done’ Novel IP2/GPU Real-Time
Search Engine for High-Throughput 4D Proteomics
At the virtual ASMS 2020 Reboot conference, Bruker Corporation
(Nasdaq: BRKR) today announces a major advance in matrix-assisted
laser desorption ionization (MALDI) with the launch of the world’s
first commercial MALDI-2 post-ionization (PI) source, which is now
available as an option on the timsTOF fleX™ ESI/MALDI mass
spectrometer. The novel MALDI-2 technology can offer one or two
orders of magnitude higher sensitivity for many small molecules and
lipids. MALDI-2 increases the applications range of MALDI mass
spectrometry and imaging even further.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200529005143/en/
(Photo: Business Wire)
Moreover, Bruker launches additional unique TIMS/PASEF-enabled
4D proteomics methods that leverage the large-scale, real-time
availability of accurate collision cross sections (CCS) for tens of
thousands of measured peptides per 4D nanoLC-CCS-MS/MS run. These
new methods and software include prm-PASEF, short-gradient
dia-PASEF, MOMA, and ‘Run and Done’ proteomics using a novel
GPU-based real-time search engine. In addition to further enhanced
peptide, protein and PTM identification, these CCS-enabled
innovations allow for sustained, ultra-high sensitivity LFQ
performance, and for truly high-throughput methods for 4D
proteomics, 4D lipidomics and 4D metabolomics on the exceptionally
robust timsTOF Pro platform.
A. SpatialOMx® and Translational Mass Spectrometry Imaging on
timsTOF fleX
The innovative MALDI-2 PI source increases both the sensitivity
and range of applications of MALDI very significantly. MALDI-2
requires a second laser (266 nm) fired orthogonally into the
expanding MALDI plume that is generated by Bruker’s proprietary
primary SmartBeam™ 3D (355 nm) laser. An optimized flexMatrix™
formulation is recommended for MALDI-2. The new MALDI-2 source is
now available as an option on the timsTOF flex ESI/MALDI
instrument.
Professor Klaus Dreisewerd, Leader Section for Biomedical
Mass Spectrometry at the University of Muenster in Germany, and the
pioneer of MALDI-2, said: “In the last 35 years, MALDI has become a
unique and rapid analytical tool for a wide variety of
applications. We developed MALDI-2 to significantly extend the
technique by providing much higher sensitivity for small molecules,
and the inclusion of chemical classes that did not ionize
efficiently with MALDI. The MALDI-2 powered timsTOF fleX will take
MALDI to new scientific and analytical frontiers.”
Dr. Michael Easterling, Global MS Imaging Director at
Bruker Daltonics, added: “The growing value of MALDI Imaging and
SpatialOMx for tissue-specific models in drug development drives
demand for even higher sensitivity and versatility. With its
dramatically increased sensitivity and accessible range of chemical
classes, the novel MALDI-2 source option can now further enhance
mass spectrometry-based, non-targeted tissue analysis.”
Bruker now also offers a MALDI-2 compound reference library for
its MetaboScape® metabolomics software, which was created during
various academic and pharma collaborations. MetaboScape provides
automatic analyte annotation within the SCiLS™ Lab MALDI imaging
software, including CCS-algorithms that improve the confidence of
annotation for many metabolites, glycans and lipids directly in
tissue images.
B. CCS-Enabled 4D Proteomics™ Innovations on timsTOF
Platform
prm-PASEF for Translational Quantitative 4D
Proteomics
Bruker’s revolutionary timsTOF™ Pro has been further
enhanced by combining PASEF® with parallel reaction monitoring
(PRM) for label-free quantitative proteomics. This unique mode of
prm-PASEF takes advantage of the 4th dimension of separation using
TIMS to improve selectivity and sensitivity, combined with the
speed of PASEF to increase the number of precursor targets. Working
closely with the Skyline team to enable prm-PASEF methods, Skyline
software can now analyze the prm-PASEF data and produce
quantitative reports.
The group of Prof. Gunnar Dittmar from the Luxembourg
Institute of Health and Prof. Antoin Lesur, who both worked
on the prm-PASEF workflow development, commented: “We have been
extremely impressed by the early results from prm-PASEF on the
timsTOF Pro in our lab. The sensitivity and speed of prm-PASEF
already rivals that of PRM methods that have been developed over
many years on other platforms.”
Dr. Jarrod Marto, Associate Professor at the Dana-Farber
Cancer Institute, Harvard Medical School, and Brigham and Women’s
Hospital added: “We have made tremendous progress since initiating
co-development of prm-PASEF with the Bruker Team. The unique
combination of acquisition speed and integrated ion mobility on the
timsTOF Pro enable us to robustly quantify potential biomarker
candidates across clinical cohorts. Moreover, real-time adjustment
of acquisition parameters with prm-PASEF LIVE will push usability
and throughput even further.”
Large-Scale, High-Precision Peptide CCS Measurements for Deep
Learning
Peptide collisional cross sections (CCS) measured at large scale
and with high precision by the unique TIMS technology deliver added
dimensionality for increased confidence of identification in 4D
proteomics. A new study by Florian Meier et. al., entitled ‘Deep
learning the collisional cross sections of the peptide universe
from a million training samples’, and submitted to bioRxiv,
(2020.05.19.102285; doi:
https://doi.org/10.1101/2020.05.19.102285), uses a deep learning
training set of 570,000 CCS values measured in 360 LC/MS runs of
fractionated digests of five organisms, run on a timsTOF Pro
system.
Professor Matthias Mann, Director at the Max Planck
Institute of Biochemistry, Germany, commented: “The size and shape
of peptide ions in the gas phase are an under-explored dimension
for mass spectrometry-based proteomics. CCS values can now be
predicted for any peptide and organism, forming a basis for
advanced proteomics workflows that make full use of the additional
information.”
Short-gradient dia-PASEF and Mobility Offset Mass Aligned
(MOMA) for 4D Proteomics
New short-gradient methods have been developed using the
dia-PASEF workflow, which is finding increasing use in many
timsTOF Pro labs. Dia-PASEF can provide a meaningful advance in
data completeness, and the dia-PASEF workflow is now supported by
Bioinformatics Solutions Inc. PEAKS and Biognosys Spectronaut
software.
Dr. Lukas Reiter, Chief Technology Officer of Biognosys
commented: “With the Spectronaut 14 launch, we have complete
support for the timsTOF Pro: Fast library generation from PASEF and
ion mobility calibration for a more specific targeted extraction in
Spectronaut. Furthermore, we have added directDIA support for the
timsTOF Pro. We are also excited to have a timsTOF Pro in our lab
to further speed up our software development for this new and
exciting platform.”
Dr. Gary Kruppa, Vice President for Proteomics at Bruker
Daltonics, added: “With the launch of prm-PASEF, the growing
success of dia-PASEF, and the trend towards shorter gradients that
take advantage of the robustness, sensitivity and unmatched
duty-cycle of PASEF, the timsTOF Pro provides the capabilities to
make 4D-proteomics ‘translational reality’. Furthermore, the unique
MOMA feature of TIMS allows for targeting isobaric precursors at
similar retention times for MS/MS acquisition. Having MOMA
capability helps improve the depth of coverage using short
gradients, and this is important to our translational research
proteomics users who are running >50 samples per day per timsTOF
Pro.”
‘Run & Done’ Real-Time Search Developed by Yates Lab for
High-Throughput 4D Proteomics
Bruker announces the availability of the proteomic pipeline
(IP2) with a GPU-based search engine incorporating the ProLuCID
database search tool from the laboratory of Professor John Yates at
The Scripps Research Institute based in LaJolla, CA. This unique
GPU-based IP2 software has been developed by Dr. Robin Park and
allows timsTOF Pro 4D data to be searched in real-time during
acquisition, with search results available at the end of the
run.
Prof. John Yates III and Dr. Robin Park said: “The
co-evolution of computational advances with mass spectrometry
sensitivity and scan speed have enabled more accurate, large-scale
data analysis approaches that help answer many biological
questions. GPU-based search engines designed to simultaneously
execute many parallel instruction threads can reduce search times
to the point where the search results can be converted into
real-time input to drive tandem MS acquisition. This becomes an
exciting part in our partnership with Bruker, as it will utilize
the timsTOF Pro even more intelligently.”
Dr. Rohan Thakur, Executive Vice President of Life
Sciences Mass Spectrometry at Bruker Daltonics, added: “The IP2/GPU
solution provides a software infrastructure that’s amenable to
supporting ‘plug-in applications’ from our third-party software
partners that take advantage of high-performance cluster or cloud
capabilities. We are committed to our strategy of open data file
formats to facilitate community-driven software development,
including our third-party partners through API access for the
benefit of the timsTOF user community.”
Featured speakers at our eXceed symposia and breakfast events.
For more detailed information on our eXceed Symposia and Breakfast
Workshops please visit
www.bruker.com/events/2020/asms-2020-reboot.
- The Synergies of Mass Spectrometry and Informatics Prof.
John Yates, The Scripps Research Institute, La Jolla, CA,
USA
- Next level imaging Mass
Spectrometry: Single cells in focus with SpatialOMx Prof.
Ron Heeren, Maastricht University, Maastricht,
Netherlands
- Clinical Proteomics in interesting
times Roman Fischer, University of Oxford, Oxford, United
Kingdom
- Developing PRM on the timsTOF Pro for biomarker studies in
cerebrospinal fluid Jarrod Marto, Dana-Farber Cancer
Institute, Harvard Medical School, Boston, MA, USA
- High-speed MALDI-2 on a timsTOF
fleX: An overview of applications Dr. Bram Heijs, Leiden
University Medical Center, Leiden, The Netherlands
- Affinity-Bead Assisted Mass Spectrometry (Affi-BAMS): A
Multiplexed Microarray Platform for Targeted Proteomics Ghaith
Hamza, Astra Zeneca, Discovery Science, MA, USA
- Kinase-substrate analysis via diaPASEF phosphoproteomics
Danielle Swaney, School of Medicine, University of
California, San Francisco, CA, USA
- PASER: Parallel Database Search Engine in Real-Time and beyond
Robin Park, The Scripps Research Institute and CEO
Integrated Proteomics Applications, La Jolla, CA, USA
- Introducing the Novel timsTOF fleX MALDI-2 a powerful tool to
enhance sensitivity and dimensionality for SpatialOMx Prof.
Klaus Dreisewerd, University of Münster, Münster, Germany
- Trapped Ion Mobility Spectrometry (TIMS) and Parallel
Accumulation Serial Fragmentation (PASEF) for Urine Metabolomic
Profiling Christina Di Poto, AstraZeneca, Gaithersburg, MD,
USA
Bruker will host a virtual scientific and trade press conference
on Monday, June 1st, 2020, at 8:00 am CDT, including Bruker
management and guest speaker Professor John Yates.
Customers are invited to visit Bruker’s ASMS 2020 Reboot virtual
hospitality suite throughout the conference.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels.
In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200529005143/en/
Media Contact: Petra Scheffer Bruker Daltonics Marketing
& Communications T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com
Investor Contact: Miroslava Minkova Director of Investor
Relations & Corporate Development T: +1 (978) 663-3660, ext.
1479 E: m.minkova@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024